Anebulo Pharmaceuticals Secures $994,300 NIH Grant for Pediatric Cannabis Toxicity Drug Trial
I'm PortAI, I can summarize articles.
Anebulo Pharmaceuticals Inc. has secured a $994,300 grant from the NIH to support its Phase 1 study of selonabant, aimed at treating acute cannabis-induced toxicity in children. The study, approved by the FDA, focuses on the drug's safety and pharmacokinetics. The company is collaborating with NIDA and the FDA to develop selonabant for pediatric use.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments